AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Cartesian Therapeutics, Inc. Director's Dealing 2019

Dec 26, 2019

33483_dirs_2019-12-26_5bd39b4d-e4f4-4ba8-a879-2e1195b406ad.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2019-12-23

Reporting Person: SPRINGER TIMOTHY A (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-12-23	Common Stock	A	3940887	$1.46	Acquired	5486463	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-12-23	Warrants	$1.46	A	1970443	Acquired	2024-12-23	Common Stock (1970443)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	7293625	Direct
Common Stock	86418	Indirect

Footnotes

F1: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.